Key facts
- · Type: New offering first sale 2026-09-09 · Amount sold: $113K · Total offering: $113K · SEC filing
- · Type: New offering first sale 2025-12-16 · Amount sold: $3.50M · Total offering: $3.50M · SEC filing
- · Type: New offering first sale 2025-09-29 · Amount sold: $4M · Total offering: $4M · SEC filing
- · Type: New offering first sale 2024-10-16 · Amount sold: $5M · Total offering: $5M · SEC filing
- · Type: New offering first sale 2024-04-30 · Amount sold: $365K · Total offering: $365K · SEC filing
Is Lexaria Bioscience Corp. a real, registered company?
Lexaria Bioscience Corp. is a registered filer with the SEC (CIK 1348362) and has filed since 2023-10-04. 7 filings are on record, the latest on 2026-09-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Lexaria Bioscience Corp.?
Lexaria Bioscience Corp.'s filings name Albert Reese, Christopher Bunka, John Docherty and 8 more as its officers, directors or promoters.
How much has Lexaria Bioscience Corp. raised?
Its new offerings report $18.15M sold across 7 offerings, as its own filings state.
Run the free check on Lexaria Bioscience Corp. →
KELOWNA, BRITISH COLUMBIA, CANADA
Biotechnology
7
$18.15M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-09-21 | New offering first sale 2026-09-09 | $113K | $113K | details · SEC filing |
| 2025-12-19 | New offering first sale 2025-12-16 | $3.50M | $3.50M | details · SEC filing |
| 2025-10-01 | New offering first sale 2025-09-29 | $4M | $4M | details · SEC filing |
| 2024-10-16 | New offering first sale 2024-10-16 | $5M | $5M | SEC filing |
| 2024-05-02 | New offering first sale 2024-04-30 | $365K | $365K | SEC filing |
| 2024-02-16 | New offering first sale 2024-02-16 | $3.60M | $3.60M | SEC filing |
| 2023-10-04 | New offering first sale 2023-10-03 | $1.57M | $1.57M | SEC filing |
Want the whole picture on Lexaria Bioscience Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexaria Bioscience Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexaria Bioscience Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Lexaria Bioscience Corp.'s own filings with the SEC. The people those filings name are on the team page.